http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1102392-A8
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f1c067d916139adf0767c09996b40c3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 |
| filingDate | 2011-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a8be039d5193aa2cb2ebe8781266d1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_527c0b6d91bf1b34109f89dc96ad0db2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c344963de6e910fed20a24758472d50d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b870db54168a6a0df88eaac757ab6f2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a34c2f99d54b332a548ae7352cf56ae6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d550a88aba9c7800366721624d91495a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2b7dd7bdbb4aea62f52fddb0a8bb496 |
| publicationDate | 2018-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI1102392-A8 |
| titleOfInvention | product containing the combination of the drug (4s) - 6-chloro - 4- (2-cyclopropylethynyl) -4- (trifluoromethyl) -1h-3,1-benzoxazin-2-one and the n-vinyl-2-pyrrolidinone polymer |
| abstract | product containing the combination of the drug (4s) -6-chloro-4- (2-cyclopropylethynyl) -4- (trifluoromethyl) -1h-3,1-benzoxazin-2-one and the polymer nv | n | ~ | This invention is intended to patent the product obtained by combining the antiretroviral drug efavirenz (efz); (4s) -6-chloro-4- (2-cyclopropylethynyl) -4- (trifluoromethyl) -1h-3,1-benzoxazin-2-one (name iupac) and the water-soluble polymer n-vinyl-2-pyrrolidinone (iupac name) (pvp) and / or its derivatives (pvp k-12, pvp k-15, pvp k-17, pvp k-25, pvp k-60, pvp k-90, and pvp k -120), resulting in a higher dissolution rate of efavirenz drug in a dissolution medium and / or increase of the percentage of dissolved drug in this medium in relation to the isolated drug. having its application in the formulation of oral and / or parenteral drugs, which are of immediate release of the drug in biological fluids in / or modified release, the basis of the drug for the treatment of acquired immunodeficiency syndrome or related diseases. Increasing the speed and / or dissolution rate of efavirenz by obtaining binary solid dispersion systems and / or physical mixtures with hydrophilic polymers such as pvp, in different proportions, provides solid and / or liquid pharmaceuticals. oral administration, with modified solubility and / or dissolution profile compared to the formulated drug based on the non-dispersed drug, giving the drug greater therapeutic efficacy and less toxicity. |
| priorityDate | 2011-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.